News

Dr. Ray discusses the impact of current practice on cholesterol goal attainment and what more needs to be done.

Dr. Green discusses the potential of combination therapy to reduce cardiovascular and kidney outcomes in people with type 2 diabetes.

Dr. Joseph discusses modalities to address cardiometabolic disease in individuals around the country, from lifestyle management to policy-level changes.

Despite the frequency in which the ARAs were detected, investigators noted that they were not associated with any noticeable patient outcomes.

The Acne-Q and the CompAQ instruments received an “A” recommendation by investigators, though evidence on content validity and other measurement properties were lacking.

Abortion is much safer than having a term delivery and actually reduces the patient's chance of death–from a purely scientific perspective, which Aziz said, is the perspective all physicians should hold when they approach difficult situations.

Dr. Rindos discusses the intricacies of diagnosing and treating uterine fibroids, which develop in the majority of women.

Between 2015-2019 the number of HBV-related deaths increased by 2.9%.

In this episode, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.

Dr. Craiglow speaks on how dermatologists can set expectations with their patients regarding the effectiveness and timeliness of current vitiligo therapies,

Dr. Karan Lal speaks on treating vitiligo in patients from across the world, and how he expects a wave of prescription requests for ruxolitinib cream following the potential FDA approval.

Dr. Cohen of Yale details new therapeutic strategies and the different cultural perspectives regarding vitiligo.

An updated review highlights both the efficacy and safety of the increasingly popular vitiligo treatment.

The issued marketing denial orders require the country's most popular vaping device company remove all commercial products on the basis of insufficient toxicity data.

Many patients with vitiligo have become disillusioned with healthcare due to a lack of long-term, effective management strategies. However, Dr. Chovatiya believes the impending ruxolitinib cream approval may signal real change in the treatment of the skin disorder.

The results show a mean VASI score prior to treatment of 0.55, which increased to 1.97 at the 6 month mark.

Dr. Arkin speaks to how the psychological burdens of vitiligo can be exacerbated in younger patients, and what anticipated approvals such as ruxolitinib cream could mean for pediatric populations.

Usage of subtenon and regional anesthesia decreased, while general and combined topical and intracameral anesthesia was stable.

New phase 3 data show a microencapsulated form of the topical antiseptic and vitamin D derivative is beneficial and tolerable over 12 weeks.

However, vision is no longer significantly improved after 4 years of using anti-VEGF therapies.

Non-vegetable nitrate intake was not associated with less frequent incident open-angle glaucoma.

After implantation, investigators observed very good distance, intermediate and near functional visual outcomes and a high percentage of subjects without visual disturbances.

This downward trend in LVS was suggested to be a product of decreased distribution of patients treated with intravitreal injections.

Low lifestyle scores were driven by non-adherence to the Mediterranean diet, with low vegetable and fish intake being most prominent.

The investigators labeled pre-existing glaucoma, high preoperative intraocular pressure, and combined keratoplasty with removal or exchange of an intraocular lens were definitely associated with an increased risk.

The aim is for the RNA-based medicine to dually serve as a treatment for multiple forms of transthyretin amyloidosis, and as a commercial contender to competing therapies.

Savanna Perry, PA-C, discussed the challenge of standing out over influencers and estheticians regarding clinical dermatology insight, and the unique offerings of different platforms.